vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 target price on the stock.

vTv Therapeutics Price Performance

NASDAQ VTVT opened at $18.20 on Monday. The stock’s 50 day simple moving average is $16.16 and its 200 day simple moving average is $15.34. vTv Therapeutics has a one year low of $12.12 and a one year high of $30.99. The firm has a market cap of $58.06 million, a PE ratio of -4.02 and a beta of 0.73.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at approximately $25,000. Geode Capital Management LLC boosted its position in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the last quarter. Finally, FMR LLC acquired a new stake in shares of vTv Therapeutics in the 3rd quarter valued at $2,402,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.